Doctors have started trialing the world’s first mRNA lung cancer vaccine, BNT116, which experts believe could revolutionise cancer treatment and save thousands of lives. Lung cancer, responsible for 1.8 million deaths annually, has poor survival rates, especially in advanced stages.
The vaccine, created by BioNTech, targets non-small cell lung cancer (NSCLC) by instructing the immune system to identify and kill cancer cells, preventing recurrence. Unlike chemotherapy, this approach aims to target cancer cells while sparing healthy ones.
The phase 1 trial, involving 130 patients from seven countries, has launched at 34 sites, including six in the UK. Patients, from early to late-stage lung cancer, will receive the vaccine alongside immunotherapy. The vaccine uses mRNA technology, similar to COVID-19 vaccines, to prime the body against tumour markers from NSCLC.
Prof. Siow Ming Lee from University College London Hospitals (UCLH), leading the UK trial, calls it a significant advancement in cancer treatment.
Janusz Racz, a 67-year-old scientist, was the first UK patient to receive the vaccine. He hopes it will help him and others. The trial aims to improve lung cancer survival rates and eventually make the vaccine a global standard of care.
#MaltaDaily